MarketPulse

immunoglobulin

2 articles
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SAB Biotherapeutics Raises $85M to Accelerate Diabetes Drug Development

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.
SABSSABSWclinical trialpublic offering